RISA Labs: Pioneering a New Era in Oncology Care with AI
April 18, 2025, 3:33 am
RISA Labs
Total raised: $3.5M
In the world of oncology, time is a precious commodity. Every moment counts when battling cancer. Yet, patients often find themselves ensnared in a web of bureaucratic delays. RISA Labs aims to cut through this red tape with its innovative AI-powered platform, BOSS. Recently, the company secured $3.5 million in seed funding to expand its reach and enhance cancer care across the United States.
Cancer treatment is not just about medicine; it’s about speed. Unfortunately, the current healthcare system is riddled with inefficiencies. Prior authorization processes can delay life-saving treatments by weeks. RISA Labs is on a mission to change that. Their platform, BOSS—Business Operating System as a Service—transforms the way healthcare organizations manage workflows.
Founded by Kshitij Jaggi and Kumar Shivang, RISA Labs is rooted in the belief that technology can streamline healthcare. Their frustration with slow, error-prone systems led them to create a solution that leverages artificial intelligence. BOSS breaks down complex workflows into manageable micro-tasks. It then assigns these tasks to a network of intelligent agents, including digital twins and reinforcement learners. This approach creates a parallel digital workforce, effectively doubling the operational capacity of healthcare institutions.
The funding round was led by Binny Bansal, co-founder of Flipkart, with support from several venture capital firms. This financial backing will allow RISA Labs to deploy its technology in 100 cancer centers across the country over the next two years. The potential impact is enormous. With BOSS, prior authorization times have been slashed from 30 minutes to under five. This is not just a minor improvement; it’s a game-changer for cancer care.
Delays in treatment can have dire consequences. Studies show that 70% of cancer patients experience delays due to prior authorization requirements. In one-third of these cases, the delay can extend to a month, increasing the risk of death by 13% for certain cancer types. The stakes are high, and RISA Labs is stepping up to address this critical issue.
BOSS is not merely another automation tool. It’s a comprehensive orchestration engine designed specifically for the complexities of healthcare. Traditional software often becomes a burden, requiring skilled labor to operate. RISA Labs aims to change this narrative. Their platform is designed for the post-ChatGPT era, where the focus shifts from learning tools to expressing intent. This shift could redefine how healthcare professionals interact with technology.
The results speak for themselves. At a leading cancer center, BOSS processed over $1 million in medications within months, freeing up 80% of staff time and cutting administrative costs by 66%. This efficiency allows healthcare teams to focus on what truly matters: patient care. As Dr. Jeffrey Vacirca, CEO of New York Cancer and Blood Specialists, noted, the technology removes barriers, enabling teams to move faster and concentrate on treating patients.
RISA Labs is not just about improving workflows; it’s about transforming the entire oncology ecosystem. The company envisions a future where coordination and intelligence flow seamlessly across providers, life sciences organizations, and other stakeholders. This holistic approach positions RISA Labs as a key player in the AI transformation of healthcare.
The founders, Jaggi and Shivang, are no strangers to the challenges of healthcare. Their previous venture, Urban Health, exposed them to the fragmented and slow processes that plague the industry. This experience fueled their desire to create a system that could integrate and streamline operations. Their research on digital twin ecosystems in oncology clinical operations laid the groundwork for BOSS, turning theoretical concepts into practical solutions.
As RISA Labs continues to grow, it signals a broader shift in enterprise AI. The company is poised to lead the charge in unbundling the $4.6 trillion services industry. With proven success in oncology, BOSS is built to scale, offering a model that could be replicated across various sectors of healthcare.
Looking ahead, RISA Labs plans to extend its reach within the oncology ecosystem. The goal is to create a unified layer for AI-driven orchestration, enhancing operational and clinical workflows. This vision aligns with the growing demand for efficiency and effectiveness in healthcare, particularly in oncology, where every second matters.
In conclusion, RISA Labs is at the forefront of a revolution in cancer care. By harnessing the power of AI, the company is dismantling the barriers that delay treatment and jeopardize patient outcomes. With significant funding and a clear vision, RISA Labs is not just changing workflows; it’s changing lives. The future of oncology care is bright, and RISA Labs is leading the way.
Cancer treatment is not just about medicine; it’s about speed. Unfortunately, the current healthcare system is riddled with inefficiencies. Prior authorization processes can delay life-saving treatments by weeks. RISA Labs is on a mission to change that. Their platform, BOSS—Business Operating System as a Service—transforms the way healthcare organizations manage workflows.
Founded by Kshitij Jaggi and Kumar Shivang, RISA Labs is rooted in the belief that technology can streamline healthcare. Their frustration with slow, error-prone systems led them to create a solution that leverages artificial intelligence. BOSS breaks down complex workflows into manageable micro-tasks. It then assigns these tasks to a network of intelligent agents, including digital twins and reinforcement learners. This approach creates a parallel digital workforce, effectively doubling the operational capacity of healthcare institutions.
The funding round was led by Binny Bansal, co-founder of Flipkart, with support from several venture capital firms. This financial backing will allow RISA Labs to deploy its technology in 100 cancer centers across the country over the next two years. The potential impact is enormous. With BOSS, prior authorization times have been slashed from 30 minutes to under five. This is not just a minor improvement; it’s a game-changer for cancer care.
Delays in treatment can have dire consequences. Studies show that 70% of cancer patients experience delays due to prior authorization requirements. In one-third of these cases, the delay can extend to a month, increasing the risk of death by 13% for certain cancer types. The stakes are high, and RISA Labs is stepping up to address this critical issue.
BOSS is not merely another automation tool. It’s a comprehensive orchestration engine designed specifically for the complexities of healthcare. Traditional software often becomes a burden, requiring skilled labor to operate. RISA Labs aims to change this narrative. Their platform is designed for the post-ChatGPT era, where the focus shifts from learning tools to expressing intent. This shift could redefine how healthcare professionals interact with technology.
The results speak for themselves. At a leading cancer center, BOSS processed over $1 million in medications within months, freeing up 80% of staff time and cutting administrative costs by 66%. This efficiency allows healthcare teams to focus on what truly matters: patient care. As Dr. Jeffrey Vacirca, CEO of New York Cancer and Blood Specialists, noted, the technology removes barriers, enabling teams to move faster and concentrate on treating patients.
RISA Labs is not just about improving workflows; it’s about transforming the entire oncology ecosystem. The company envisions a future where coordination and intelligence flow seamlessly across providers, life sciences organizations, and other stakeholders. This holistic approach positions RISA Labs as a key player in the AI transformation of healthcare.
The founders, Jaggi and Shivang, are no strangers to the challenges of healthcare. Their previous venture, Urban Health, exposed them to the fragmented and slow processes that plague the industry. This experience fueled their desire to create a system that could integrate and streamline operations. Their research on digital twin ecosystems in oncology clinical operations laid the groundwork for BOSS, turning theoretical concepts into practical solutions.
As RISA Labs continues to grow, it signals a broader shift in enterprise AI. The company is poised to lead the charge in unbundling the $4.6 trillion services industry. With proven success in oncology, BOSS is built to scale, offering a model that could be replicated across various sectors of healthcare.
Looking ahead, RISA Labs plans to extend its reach within the oncology ecosystem. The goal is to create a unified layer for AI-driven orchestration, enhancing operational and clinical workflows. This vision aligns with the growing demand for efficiency and effectiveness in healthcare, particularly in oncology, where every second matters.
In conclusion, RISA Labs is at the forefront of a revolution in cancer care. By harnessing the power of AI, the company is dismantling the barriers that delay treatment and jeopardize patient outcomes. With significant funding and a clear vision, RISA Labs is not just changing workflows; it’s changing lives. The future of oncology care is bright, and RISA Labs is leading the way.